Bionano Genomics raises $10M via registered direct offering of common stock and warrants at $1.145/share

Bionano Genomics, Inc.

Issues 8.73M shares (or equivalents) and warrants to purchase 8.73M shares at $1.02; exercise price $1.02, 5-year term.
Gross proceeds ~$10M; net proceeds for working capital, R&D, debt repayment, and capex.
Expected closing on April 8, 2024; H.C. Wainwright acts as sole placement agent with 6% cash fee.
Offered under effective shelf registration statement (File No. 333-270459); warrants include beneficial ownership limitations of 4.99%/9.99%.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Bionano Genomics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $10.0 million (effective 2024-04-04).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $10.0 million
Effective: 2024-04-04

Exact text from the filing

On April 4, 2024, Bionano Genomics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market consistent with the rules of the Nasdaq Stock Market (the “Registered Direct Offering”): (i) an aggregate of 6,536,682 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), (ii) pre-funded warrants to purchase up to an aggregate of 2,196,944 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 8,733,626 shares of Common Stock (the “Warrants”).

View on SEC.gov

Browse all material agreements →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-018181

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.